The company possesses a proprietary technology platform focused on discovering and developing peptide-based new chemical entities that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. With a robust cash position of $678.8 million, the company has a runway through 2028, positioning it to advance its pipeline toward commercialization.
Cyborg Score Rationale
Protagonist remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. The company has strong financial backing and near-term catalysts, though execution risk remains significant given the clinical-stage nature of its pipeline.
Top Insights
Protagonist anticipates NDA approval and commercialization of icotrokinra and rusfertide in 2026
Icotrokinra (formerly JNJ-2113) is a first-in-class investigational targeted oral peptide licensed to Janssen Biotech, a Johnson & Johnson company, with J&J responsible for Phase 2 development onward
PN-477 is positioned as a potential best-in-class obesity treatment offering weight loss comparable to injectable treatments with oral flexibility
Analyst consensus rating is Buy from 13 analysts with a price target of $82.85
Named Competitors
Deucravacitinib — Oral JAK3 inhibitor for psoriasis
Rinvoq — Oral JAK inhibitor for inflammatory conditions
Stelara — IL-23 and IL-12 inhibitor for psoriasis and IBD
Skyrizi — IL-23 monoclonal antibody for psoriasis
Recent Developments
(January 2026) Diversified pipeline update released with focus on icotrokinra and rusfertide blockbuster potential
(December 2025) Rusfertide NDA submitted for polycythemia vera treatment
(July 2025) Icotrokinra NDA submitted for plaque psoriasis treatment
(Q4 2025) Phase 1 study initiated for PN-881, an oral IL-17 antagonist
Open the full interactive Protagonist Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.